Showing results (1141-1150 of 3,033) with videos related to

Sort By:
Pageof 304
International Journal of Clinical Pharmacology and Therapeutics|July 1, 1997
Is the biopharmaceutical quality of extracts adequate for clinical pharmacology?D Loew
International Journal of Clinical Pharmacology and Therapeutics|March 26, 2002
Treatment behavior of doctors regarding Helicobacter pylori infectionsE Perez, D Schröder-Bernhardi, G Dietlein
International Journal of Clinical Pharmacology and Therapeutics|March 26, 2002
Assessment of ADRs associated with lipid-lowering agents recorded in the Department of Internal Medicine, University Hospital, JenaM Hippius, K Farker, S Helble, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 26, 2002
The epiphany of data warehousing technologies in the pharmaceutical industryJ S Barrett, S P Koprowski
International Journal of Clinical Pharmacology and Therapeutics|January 1, 1995
Adverse drug reactions (ADRs) in patients with previous history of chronic alcohol consumption without signs of chronic hepatic damage. A prospective studyG Gonzáles-Martín, H Dominichinni, M Díaz, et al.
International Journal of Clinical Pharmacology and Therapeutics|July 1, 1994
Dose-related protection against histamine-induced bronchoconstriction by inhaled salmeterolJ G Maconochie, L H Denyer, H Hassani
International Journal of Clinical Pharmacology and Therapeutics|July 1, 1994
Modulation by adenosine of thromboxane A2 receptor-mediated constriction in the human umbilical arteryA Di Grande, L S Malatino, A L Boura, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 21, 2009
Population pharmacokinetics of albendazole in patients with neurocysticercosisN Castro, C Márquez-Caraveo, R C Brundage, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 9, 2010
The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbilR Lal, J Sukbuntherng, W Luo, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 9, 2010
Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in GermanyS Pscherer, E S Dietrich, F-W Dippel, et al.
Pageof 304